Organometallic Chemistry: Volume 38 (Specialist Periodical Reports - Organometallic Chemistry)

Product description From the Back Cover A series of critical reviews and perspectives focussing on specific aspects of organometallic chemistry interfacing with other fields of study are provided. For this volume, the critical reviews cover topics such as the activation of "inert" carbon-hydrogen bonds, ligand design and organometallic radical species. For example, Charlie O'Hara discusses how mixed-metal compounds may perform the highly selective activation of C-H bonds and, in particular, how synergic relationships between various metals are crucial to this approach. The chemistry of a remarkable series of air-stable chiral primary phosphine ligands is discussed in some depth by Rachel Hiney, Arne Ficks, Helge M³ller-Bunz, Declan Gilheany and Lee Higham. This article focuses on the preparation of these ligands and also how they may be applied in various catalytic applications. Bas De Bruin reports on how ligand radical reactivity can be employed in synthetic organometallic chemistry and catalysis to achieve selectivity in radical-type transformations. Valuable and informative comprehensive reviews in the field of organometallic chemistry are also covered in this volume. For example, organolithium and organocuprate chemistry are reviewed by Joanna Haywood and Andrew Wheatley; aspects in Group 2 (Be-Ba) and Group 12 (Zn-Hg) compounds by Robert Less, Rebecca Melen and Dominic Wright; metal clusters by Mark Humphrey and Marie Cifuentes; and recent developments in the chemistry of the elements of Group 14 - focusing on low-coordination number compounds by Richard Layfield. This volume therefore covers many synthetic and applied aspects of modern organometallic chemistry which ought to be of interest to inorganic, organic and applied catalysis fields. About the Author Professor Ian Fairlamb's core interests are in transition metal chemistry in synthetic organic chemistry, catalyst design and mechanistic understanding. His work has strong links to biological chemistry, particularly the utilisation of transition metal chemistry in the synthesis of therapeutic agents such as CO releasing molecules and functionalised heteroaromatic compounds. Dr Lynam's main research interest is in the synthesis of transition metal complexes containing nucleobases with a view to utilising the hydrogen bonding properties of these species to direct the self assembly of supramolecular organometallic architectures. Excerpt. © Reprinted by permission. All rights reserved. Organometallic Chemistry Volume 38A Review of the Recent LiteratureBy Ian J. S. Fairlamb, Jason M. LynamThe Royal Society of ChemistryCopyright © 2012 The Royal Society of ChemistryAll rights reserved.ISBN: 978-1-84973-376-2ContentsPreface Ian J. S. Fairlamb and Jason M. Lynam, v, New developments in the biomedical chemistry of metal complexes: from small molecules to nanotheranostic design Rory L. Arrowsmith, Sofia I. Pascu and Hubert Smugowski, 1, Air-stable chiral primary phosphines part (ii) predicting the air-stability of phosphines Beverly Stewart, Anthony Harriman and Lee J. Higham, 36, Organometallics aspects of C–H bond activation/functionalization Anant R. Kapdi, 48, Organo-transition metal cluster complexes Mark G. Humphrey and Marie P. Cifuentes, 75, Alkali/coinage metals – organolithium, organocuprate chemistry Philip J. Harford and Andrew E. H. Wheatley, 91, Group 2 (Be–Ba) and group 12 (Zn–Hg) Sarah B. J. Dane, Timothy C. King and Dominic S. Wright, 112, CHAPTER 1New developments in the biomedical chemistry of metal complexes: from small molecules to nanotheranostic designRory L. Arrowsmith, Sofia I. Pascu and Hubert SmugowskiDOI: 10.1039/9781849734868-00001IntroductionMolecular imaging is a key area for development worldwide. In 2007, this was defined by the Society of Nuclear Medicine as a new interdisciplinary research field, which is at the interface between clinical and preclinical research. This is highlighted by the increasing demand for new imaging probes for specific biological targets. By the end of 2010 more than 3.2 million positron emission tomography (PET) studies have been carried out worldwide. It is widely recognised that optimal disease management is achieved by monitoring patient status before, during and after therapy. PET agents offer high resolution, noninvasive imaging with provision of invaluable diagnosis of biological function at agent concentrations below the pharmacological threshold. There is currently intense interest in the development of new PET agents for imaging a wide range of disease states, and of new drugs for targeted radiotherapy. Drugs containing a radio-nuclide are known as radiopharmaceuticals and can be used for diagnosis and/or therapy. Radiopharmaceuticals chosen for the purpose of diagnosis are usually positron emitters (PET) or gamma emitters (SPECT), whereas therapeutic radiopharmaceuticals usually rely upon β- emission and the Auger effect causing cell death. The choice of radioisotope is also made accord